Literature DB >> 30389491

Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population.

Zelma C Chiesa Fuxench1, Julie K Block2, Mark Boguniewicz3, John Boyle4, Luz Fonacier5, Joel M Gelfand6, Mitchell H Grayson7, David J Margolis6, Lynda Mitchell8, Jonathan I Silverberg9, Lawrence Schwartz10, Eric L Simpson11, Peck Y Ong12.   

Abstract

Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9-8.8). Overall, 60.1% (56.1-64.1) of participants were classified as having mild, 28.9% (25.3-32.7) as having moderate, and 11% as having severe (8.6-13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients = 4.71 [6.44] vs. control individuals = 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard deviation] for AD patients = 7.03 [4.80] vs. control individuals = 4.73 [4.8]) and depression (mean, [standard deviation] for AD patients = 5.83 [4.54] vs. control individuals = 3.62 [3.61]) scales, indicating a worse impact on quality of life and an increased likelihood of anxiety or depression. Based on our prevalence estimates, 16.5 million adults would have a diagnosis of atopic dermatitis, with 6.6 million meeting criteria for moderate to severe disease. Our study confirms the high prevalence and disease burden of atopic dermatitis in this population.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30389491     DOI: 10.1016/j.jid.2018.08.028

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  58 in total

1.  Glioma incidence and survival variations by county-level socioeconomic measures.

Authors:  David J Cote; Quinn T Ostrom; Haley Gittleman; Kelsey R Duncan; Travis S CreveCoeur; Carol Kruchko; Timothy R Smith; Meir J Stampfer; Jill S Barnholtz-Sloan
Journal:  Cancer       Date:  2019-06-17       Impact factor: 6.860

Review 2.  Atopic Dermatitis: Epidemiology and Clinical Phenotypes.

Authors:  Annunziata Raimondo; Serena Lembo
Journal:  Dermatol Pract Concept       Date:  2021-10-01

3.  Prevalence of eczema among adults in the United States: a cross-sectional study in the All of Us research program.

Authors:  Audrey C Leasure; Jeffrey M Cohen
Journal:  Arch Dermatol Res       Date:  2022-02-11       Impact factor: 3.017

4.  Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence.

Authors:  Carolyn Lou; Nandita Mitra; Bradley Wubbenhorst; Kurt D'Andrea; Ole Hoffstad; Brian S Kim; Albert Yan; Andrea L Zaenglein; Zelma Chiesa Fuxench; Katherine L Nathanson; David J Margolis
Journal:  Ann Allergy Asthma Immunol       Date:  2019-09-04       Impact factor: 6.347

5.  HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study.

Authors:  David J Margolis; Nandita Mitra; Brian S Kim; Jamie L Duke; Ron A Berna; Ole J Hoffstad; Jenna R Wasserman; Deborah A Ferriola; Tim L Mosbruger; Bradley S Wubbenhorst; Kathrine L Nathanson; Dimitri S Monos
Journal:  J Immunol       Date:  2021-04-16       Impact factor: 5.422

6.  Mental Health Symptoms and Functional Impairment in Children With Atopic Dermatitis.

Authors:  Brian T Cheng; Anna B Fishbein; Jonathan Ian Silverberg
Journal:  Dermatitis       Date:  2021 Sep-Oct 01       Impact factor: 4.845

7.  Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database.

Authors:  Kristin J Meyers; Jonathan I Silverberg; Maria Jose Rueda; Robert Goodloe; Evangeline J Pierce; Walter Deberdt; Dennis R Brinker
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-30

8.  Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.

Authors:  Xiaohua Gong; Xuejun Chen; Michael E Kuligowski; Xing Liu; Xiang Liu; Evan Cimino; Ryan McGee; Swamy Yeleswaram
Journal:  Am J Clin Dermatol       Date:  2021-05-12       Impact factor: 7.403

9.  What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.

Authors:  J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu
Journal:  Br J Dermatol       Date:  2020-09-21       Impact factor: 9.302

10.  Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors.

Authors:  Christopher H Arehart; Michelle Daya; Monica Campbell; Meher Preethi Boorgula; Nicholas Rafaels; Sameer Chavan; Gloria David; Jon Hanifin; Mark K Slifka; Richard L Gallo; Tissa Hata; Lynda C Schneider; Amy S Paller; Peck Y Ong; Jonathan M Spergel; Emma Guttman-Yassky; Donald Y M Leung; Lisa A Beck; Christopher R Gignoux; Rasika A Mathias; Kathleen C Barnes
Journal:  J Allergy Clin Immunol       Date:  2021-06-07       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.